16 results about "Reuptake inhibitor" patented technology

The invention discloses a hierarchical encryption storage system and management method for multi-dimensional anti-depression drug component data in the field of medical data security and information management. The hierarchical encryption storage system comprises a data acquisition layer, a sensitivity hierarchical module, a multi-dimensional encryption engine, a distributed storage cluster, an access control center, a key management system and an audit traceability module. The data acquisition layer is used for acquiring and standardizing multi-dimensional component data of the anti-depression drug; the sensitivity layering module calculates a data sensitivity index S based on an entropy method, and divides data into a public layer, an internal layer and a core layer. The method solves the problems of coarse encryption granularity, rigid authority management and weak anti-attack ability in the storage of the existing anti-depression drug component data (such as the molecular structure and curative effect data of a 5-hydroxytryptamine reuptake inhibitor), reduces the data leakage rate by 92% or more, improves the access efficiency by 40%, and has good application prospects. The method is suitable for sensitive data full-life-cycle management of pharmaceutical enterprises and medical institutions.

Provided herein are methods of treating symptoms associated with menopause, perimenopause and / or post-menopause in a subject in need thereof by administering to the subject compositions comprising a triple reuptake inhibitor (e.g., Compound 1).

The present invention provides a monoamine transmitter reuptake inhibitor and a preparation method therefor and a pharmaceutical composition thereof, and further relates to a use of the compound or the pharmaceutical composition in preparation of a drug for preventing or treating dopamine (DA), norepinephrine (NE), 5-hydroxytryptamine (5-HT), and / or sigma-1 receptor-mediated related diseases.

This article provides a method for treating sleep disorders (e.g., narcolepsy) in subjects who require it by administering a composition containing a triple reuptake inhibitor to the subject.

The invention provides a monoamine transmitter reuptake inhibitor as well as a preparation method and a pharmaceutical composition thereof. The invention also relates to application of the compound or the pharmaceutical composition in preparation of drugs for preventing or treating dopamine DA, noradrenaline NE, 5-hydroxytryptamine 5-HT and / or sigma-1 receptor mediated related diseases.

The present invention aims to provide a serotonin uptake inhibitor that can exert its effects more efficiently by analyzing the component composition of plants of the genus Valerian. [Solution] The present invention provides a serotonin reuptake inhibitor comprising a compound represented by the following formula (1), and one or more selected from the group consisting of the compound, canoconyl acetate, and α-kesyl acetate as active ingredients. [Formula 1] TIFF2026060423000008.tif50170

Galanin (1-15) and fluoxetine in the treatment of treatment-resistant depression, GAL (1-15) in combination with a seratonin reuptake inhibitor, preferably fluoxetine, for use in the treatment of treatment-resistant depression, and a composition comprising same.

The present invention relates to a method for intelligently constructing a list of preferred 5-hydroxytryptamine reuptake inhibitors. The method comprises the following steps: constructing a functional receptor protein of a 5-hydroxytryptamine reuptake inhibitor by a homology modeling method, screening its key protein of interference with human health based on a harmful outcome pathway method, and calculating the binding energy between it and the receptor protein. The method further calculates the comprehensive effect value as the dependent variable by using an information weighting method, screening the main features of the target as the independent variable based on a variance filtering coupled Pearson correlation coefficient method, realizing the establishment of a data set, and coupling a GRU neural network with a 1D-CNN neural network to realize the intelligent construction of a list of preferred 5-hydroxytryptamine reuptake inhibitors. The present invention aims to overcome the inability of current traditional methods to comprehensively evaluate the comprehensive selection effect of the functionality of 5-hydroxytryptamine reuptake inhibitors and interference with human health, and to realize the intelligent construction of a list of preferred 5-hydroxytryptamine reuptake inhibitors with high priority by establishing a deep learning model.

Provided herein are methods of treating symptoms associated with menopause, perimenopause and / or post-menopause in a subject in need thereof by administering to the subject compositions comprising a triple reuptake inhibitor (e.g., Compound 1).

Pharmaceutical compositions containing a dopamine Putamen reuptake inhibitor or a dopaminergic agonist, an adrenoceptor antagonist, and a pharmaceutically acceptable carrier, and methods for treating neurological diseases by administering the composition.

Accurate diagnosis and treatment planning for PTSD is difficult. The discovery of specific markers creates new opportunities for more accurate clinical assessments identifying groups that may experience better outcomes when exposed to an intervention. Embodiments include methods of determining a subject's susceptibility (i.e., risk) of developing PTSD after a traumatic event. An assay can detect specific markers (e.g., nucleotides or proteins) in a sample from a subject that is prone to PTSD or suspected of suffering from PTSD. A subject who is deemed at risk of PTSD or who is suffering from PTSD can be treated with, for example, psychotherapy (e.g., cognitive behavioral therapy and adjunct pharmacotherapy) and / or medications such as serotonin-specific reuptake inhibitor (SSRI's).

The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

Provided herein are methods of treating atypical depression in a subject in need thereof by administering to the subject compositions comprising a triple reuptake inhibitor, having the structure of Compound (1).

The invention provides a monoamine transmitter reuptake inhibitor as well as a preparation method and a pharmaceutical composition thereof. The invention further relates to application of the compound or the pharmaceutical composition in preparation of drugs for preventing or treating related diseases mediated by dopamine DA, noradrenaline NE and 5-hydroxytryptamine 5-HT.

The invention belongs to the field of medicine research and development, and in order to solve the clinical oncology problem of depression of advanced cancer patients, a novel prodrug is developed, and the depression symptom is improved while cancer cells are targeted. The prodrug is a prodrug of PCPA and venlafaxine and shows effective binding affinity with human LSD 1 enzyme, and the LSD 1 enzyme is a biomarker and is also a molecular target for cancer treatment. An in-vitro research shows that the prodrug effectively occupies a PCPA binding site in the LSD 1 protein, and shows a strong inhibition effect on the proliferation of MDA-MB-231. In-vivo studies show that the previous dosage reduces the immobility time in a mouse tail suspension test in a dependent manner, and compared with the desvenlafaxine succinate (DVS), the desvenlafaxine succinate has a higher curative effect. The prodrug has dual functions: as a novel triple reuptake inhibitor, the prodrug can effectively relieve depressive symptoms, and as an LSD 1 inhibitor, the prodrug plays a role and shows an anti-cancer characteristic.